JPH06507184A - 光保護フィルターとしてのベンズイミダゾール誘導体の使用 - Google Patents
光保護フィルターとしてのベンズイミダゾール誘導体の使用Info
- Publication number
- JPH06507184A JPH06507184A JP5513733A JP51373393A JPH06507184A JP H06507184 A JPH06507184 A JP H06507184A JP 5513733 A JP5513733 A JP 5513733A JP 51373393 A JP51373393 A JP 51373393A JP H06507184 A JPH06507184 A JP H06507184A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- carbon atoms
- groups
- ethylhexyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title claims description 5
- 230000003711 photoprotective effect Effects 0.000 title claims description 5
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 43
- -1 2-ethylhexyloxy group Chemical group 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 35
- 239000002537 cosmetic Substances 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 9
- 150000001556 benzimidazoles Chemical class 0.000 claims description 6
- 230000004224 protection Effects 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 239000012071 phase Substances 0.000 description 36
- 239000003921 oil Substances 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000002844 melting Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000001993 wax Substances 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000004166 Lanolin Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000019388 lanolin Nutrition 0.000 description 9
- 229940039717 lanolin Drugs 0.000 description 9
- 230000002335 preservative effect Effects 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000475 sunscreen effect Effects 0.000 description 6
- 239000000516 sunscreening agent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 3
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Inorganic materials [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- FYNJWLOOBINARS-UHFFFAOYSA-N 3-chlorooctane Chemical compound CCCCCC(Cl)CC FYNJWLOOBINARS-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000178435 Eliokarmos dubius Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- YRHFVYBNFWWAEN-UHFFFAOYSA-M [Na+].[Cl-].OS(O)=O Chemical compound [Na+].[Cl-].OS(O)=O YRHFVYBNFWWAEN-UHFFFAOYSA-M 0.000 description 1
- FQBWIAATJXZQKY-UHFFFAOYSA-N [S].[S].[Na] Chemical compound [S].[S].[Na] FQBWIAATJXZQKY-UHFFFAOYSA-N 0.000 description 1
- UUPHVTQVPXQGSK-UHFFFAOYSA-N [bis(hydroxymethyl)amino]methanol;methane Chemical compound C.OCN(CO)CO UUPHVTQVPXQGSK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- KZLCCMBSJDXNDG-UHFFFAOYSA-N azepan-1-yl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCCCCC1 KZLCCMBSJDXNDG-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1 基R1ないしR4の少なくとも一つあるいはグループArのアルキルあるい はアルコキシ置換基が少なくとも4個の炭素原子を含有していることを特徴とす る化粧品処方中の光保護フィルターとして式Iのベンズイミダゾール誘導体の使 用、 ▲数式、化学式、表等があります▼I この式において R1、R2、R3およびR4は互いに独立であり、それぞれの場合にH、1ない し10個の炭素原子を有するアルキルあるいはアルコキシであり、Arは置換さ れてないフェニルあるいは1ないし10個の炭素原子を有する1−5アミノアル キル、アルキル、(シクロ)アルコキシ、ヒドキシルあるいはヒドロキシアルコ キシグループで置換されているフェニルあるいは1ないし10個の炭素原子を有 する1ないし2個のアルキルグループで−置換されているベンズイミダゾール− 2−イル−フェニルである。 2 請求項1による式Iaのべンズイミダゾールの使用、 ▲数式、化学式、表等があります▼Iaこの式においてはグループR1ないしR 9の少なくとも一つは4ないし10個の炭素原子を有するアルキルあるいはアル コキシであり、その他のグループR1ないしR9はH、1ないし10個の炭素原 子を有するアルキルあるいはアルコキシである。 3 式Iaのべンズイミダゾール、この式においてはグループR1ないしR9の 少なくとも一つが2−エチルヘキシルオキシグループであり、その他のグループ R1ないしR9がH、1ないし10個の炭素原子を有するアルキルあるいはアル コキシである。 4 化粧品に適合する担体中で光保護フィルターとして請求項1による式Iの少 なくとも1種の化合物の有効量からなることを特徴とする化粧品処方。 5 化粧品処方が式Iの少なくとも1種の化合物からなることを特徴とする、担 体が少なくとも1種の脂肪相から成るような請求項4による化粧品処方。 6 化粧品処方が式Iの少なくとも1種の化合物0.5ないし10重量%から成 ることを特徴とする請求項4ないし5の1項による化粧品処方。 7 化粧品処方が追加的にUV−Bフィルターを含有していることを特徴とする 請求項4ないし6の1項による化粧品処方。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4204257 | 1992-02-13 | ||
DE4204257.7 | 1992-02-13 | ||
PCT/EP1993/000233 WO1993015712A1 (de) | 1992-02-13 | 1993-02-02 | Verwendung von benzimidazol-derivaten als lichtschutzfilter |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06507184A true JPH06507184A (ja) | 1994-08-11 |
JP3637055B2 JP3637055B2 (ja) | 2005-04-06 |
Family
ID=6451602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51373393A Expired - Fee Related JP3637055B2 (ja) | 1992-02-13 | 1993-02-02 | 光保護フィルターとしてのベンズイミダゾール誘導体の使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5501850A (ja) |
EP (1) | EP0581955B1 (ja) |
JP (1) | JP3637055B2 (ja) |
DE (1) | DE59304173D1 (ja) |
ES (1) | ES2093977T3 (ja) |
WO (1) | WO1993015712A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069565A1 (ja) * | 2005-12-12 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | 二環式複素環化合物 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59509233D1 (de) * | 1994-02-24 | 2001-06-13 | Haarmann & Reimer Gmbh | Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren |
US6153176A (en) * | 1995-01-20 | 2000-11-28 | The Procter & Gamble Company | Low pH sunscreen compositions |
AT408067B (de) * | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung |
US6228871B1 (en) | 1995-07-10 | 2001-05-08 | Merck & Co., Inc. | Angiogenesis inhibitors |
DE19648010A1 (de) * | 1996-11-20 | 1998-05-28 | Haarmann & Reimer Gmbh | Verwendung von substituierten Benzazolen als UV-Absorber, neue Benzazole und Verfahren zu ihrer Herstellung |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
FR2780279B1 (fr) * | 1998-06-26 | 2001-02-02 | Oreal | Compositions cosmetiques pour la photoprotection de la peau et/ou des cheveux contenant un benzazole n-substitue et une silicone organomodifiee non-filtrante |
EP1109555A4 (en) * | 1998-08-31 | 2001-11-21 | Merck & Co Inc | NEW ANGIOGENIC INHIBITORS |
US6132739A (en) * | 1998-09-01 | 2000-10-17 | Amway Corporation | Makeup compositions and methods of making same |
DE10021468A1 (de) * | 2000-05-04 | 2001-11-08 | Basf Ag | Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen |
FR2816842B1 (fr) * | 2000-11-17 | 2005-03-11 | Oreal | Filtres uv organiques insolubles et leur utilisation en cosmetique |
DE10111728A1 (de) * | 2001-03-09 | 2002-09-12 | Merck Patent Gmbh | UV-Filter |
FR2833164B1 (fr) | 2001-12-07 | 2004-07-16 | Oreal | Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations |
WO2014010099A1 (en) | 2012-07-13 | 2014-01-16 | L'oreal | Composite pigment and method for preparing the same |
WO2014010100A1 (en) | 2012-07-13 | 2014-01-16 | L'oreal | Cosmetic composition comprising composite sunscreen particles |
JP6096897B2 (ja) | 2012-07-13 | 2017-03-15 | ロレアル | 化粧料組成物 |
EP2872106B2 (en) | 2012-07-13 | 2023-08-02 | L'oreal | Composite pigment and method for preparing the same |
FR2993176B1 (fr) | 2012-07-13 | 2014-06-27 | Oreal | Composition cosmetique contenant des particules composites filtrantes de taille moyenne superieure a 0,1 micron et des particules de filtre inorganique et une phase aqueuse |
EP2945602B1 (en) | 2013-01-21 | 2018-01-10 | L'Oréal | Cosmetic or dermatological composition comprising a merocyanine and an insoluble organic uv-screening agent and/or an insoluble inorganic uv- screening agent |
WO2016030839A1 (fr) | 2014-08-28 | 2016-03-03 | L'oreal | Composition gel/gel comprenant un filtre uv |
WO2016083404A1 (fr) | 2014-11-24 | 2016-06-02 | L'oreal | Composition cosmetique comprenant un phyllosilicate synthetique et un polyol et/ou un filtre uv |
FR3037243B1 (fr) | 2015-06-11 | 2018-11-16 | L'oreal | Composition comprenant un filtre uv, un polymere hydrophile reticule anionique, un tensioactif ayant une hlb inferieure ou egale a 5 et un copolymere silicone |
FR3073408B1 (fr) | 2017-11-15 | 2019-10-11 | L'oreal | Compositions comprenant au moins un polymere acrylique et au moins un filtre organique insoluble |
WO2019099777A2 (en) * | 2017-11-17 | 2019-05-23 | The Scripps Research Institute | Bis-benzimidazole compounds and methods of using same |
FR3083093A1 (fr) | 2018-06-28 | 2020-01-03 | L'oreal | Composition photoprotectrice comprenant des particules de silice colloidale |
FR3090329B1 (fr) | 2018-12-21 | 2020-12-04 | Oreal | Composition comprenant un filtre UV, un polymère hydrophile réticulé anionique, un tensioactif ayant une HLB inférieure ou égale à 5 et un alcane non volatil |
FR3103705B1 (fr) | 2019-11-29 | 2021-12-17 | Oreal | Composition comprenant un filtre UV, un polymère séquencé à groupe acide phosphonique et une huile hydrocarbonée |
FR3103704B1 (fr) | 2019-11-29 | 2022-07-08 | Oreal | Composition comprenant un filtre UV, un polymère éthylénique à groupe acide phosphonique et une huile hydrocarbonée |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH350763A (de) * | 1958-10-14 | 1960-12-15 | Ciba Geigy | Verwendung von Azolverbindungen als Schutzmittel gegen ultraviolette Strahlung |
CH483276A (de) * | 1959-09-23 | 1969-12-31 | Ciba Geigy | Verwendung von 2-Phenyl-benzazolen als Schutzmittel vor ultravioletter Strahlung ausserhalb der Textilindustrie |
GB1004073A (en) * | 1962-08-13 | 1965-09-08 | Merck & Co Inc | Veterinary antihelmintic compositions comprising benzimidazole derivatives |
US3535331A (en) * | 1967-07-26 | 1970-10-20 | Merck & Co Inc | Water-soluble 2-substituted benzimidazole hypophosphite salts |
FR2592380B1 (fr) * | 1985-12-30 | 1988-03-25 | Oreal | Nouveaux derives du 3-benzylidene camphre contenant des motifs benzimidazole, benzoxazole ou benzothiazole, leur procede de preparation et leur utilisation en cosmetique pour la protection contre les rayons uv |
DE3830060A1 (de) * | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
FR2677020B1 (fr) * | 1991-05-31 | 1993-08-27 | Cird Galderma | Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique. |
-
1993
- 1993-02-02 EP EP93917380A patent/EP0581955B1/de not_active Expired - Lifetime
- 1993-02-02 US US08/133,071 patent/US5501850A/en not_active Expired - Lifetime
- 1993-02-02 DE DE59304173T patent/DE59304173D1/de not_active Expired - Fee Related
- 1993-02-02 JP JP51373393A patent/JP3637055B2/ja not_active Expired - Fee Related
- 1993-02-02 ES ES93917380T patent/ES2093977T3/es not_active Expired - Lifetime
- 1993-02-02 WO PCT/EP1993/000233 patent/WO1993015712A1/de active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069565A1 (ja) * | 2005-12-12 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | 二環式複素環化合物 |
Also Published As
Publication number | Publication date |
---|---|
US5501850A (en) | 1996-03-26 |
EP0581955A1 (de) | 1994-02-09 |
ES2093977T3 (es) | 1997-01-01 |
DE59304173D1 (de) | 1996-11-21 |
WO1993015712A1 (de) | 1993-08-19 |
JP3637055B2 (ja) | 2005-04-06 |
EP0581955B1 (de) | 1996-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06507184A (ja) | 光保護フィルターとしてのベンズイミダゾール誘導体の使用 | |
US5705169A (en) | Ketotricyclo .5.2.1.0! decane derivatives | |
US5730960A (en) | Benzylidenenorcamphor derivatives | |
JP2675006B2 (ja) | 新規な日やけどめ剤 | |
US4775526A (en) | 3-benzylidene benzheterazoles in ultraviolet screening compositions | |
US5520906A (en) | Triazine derivatives with UV filter properties | |
JP2002047275A (ja) | Uv−bフィルタ | |
US5677314A (en) | Bis(methylidene)phenylene derivatives | |
JPS63165310A (ja) | 光に安定な化粧品組成物 | |
US5399563A (en) | Benzylidenequinuclidinones | |
JP3654455B2 (ja) | 光に安定な化粧品組成物 | |
JP2002053559A (ja) | 紫外線フィルタ物質の製造方法 | |
JP2001505566A (ja) | ヒトや動物の皮膚および毛をuv照射の有害な影響から保護するための、選択されたベンゾトリアゾール誘導体の使用 | |
DE3833706C2 (de) | Neue t-Butylderivate von Benzylidenkampfer, Verfahren zu ihrer Herstellung sowie sie enthaltende pharmazeutische und kosmetische Mittel | |
JP3195001B2 (ja) | ジアルコキシベンジリデンカンファー誘導体 | |
US5968482A (en) | α-hydroxyketoalkyl derivatives as light protection filters | |
US5628988A (en) | Ketotricyclo[5.2.1.0]decane derivatives | |
DE4107489A1 (de) | Kosmetische mittel, die 2-(3'-arylacryloyl)benzimidazol-derivate enthalten, neue 2-(3'-arylacryloyl)benzimidazol-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
DE4302796A1 (en) | Use of 2-phenyl benzimidazole derivs. with alkyl or alkoxy substits. - in cosmetics as filter protecting against light, for use on skin and hair | |
JP3570716B6 (ja) | 光保護フィルターとしてのα−ヒドロキシケトアルキル誘導体の使用 | |
JPS58109454A (ja) | グリセリル化合物及び紫外線吸収剤 | |
JPH01211546A (ja) | 不飽和3―ベンジリデンカンファー誘導体および化粧品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031222 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20031222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040518 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050107 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |